This actually makes me angry, you have a Covid test in Argentina and yet, almost a year after reduce-it results Amarin has not partnered, nor filed for CVD risk reduction in Argentina. I have been harping on them for awhile on this. It’s ok to drag out an EU decision if you are looking to sell the company but you create more shareholder value if V is available everywhere.
A couple of interesting points I found on the study: 1. Very quick enrollment where Dr Diaz feels confident that the 1500 studied individuals will be enrolled within a month 2. Two month study 3. Randomized and placebo controlled No guarantees but I could see this study completed and possibly reported by end of year? I guess we’ll see. Could be another huge revelation in the benefits of V if successful. 30% would be incredible if this doctors assumptions come to fruition.